As much as i agree with your post i'm also of the belief that the quality of the RNS is very important, subtle use of wording can make or break the credibilty of the BoD. Lets hope the next RNS is both full of good content and also written well. This is a reminder for BIO investors that period of quiet can really effect the value of their holding, I really hope that In-human trials start ASAP so we can get some Data because imho thats when the true value will be both created and realised.
L1onHeart is a regular poster on the MAGP board and an Ex MM, thus his post are very informative on the games played by such....he said recently that everyone knows that shares drift down on no news on AIM, and thus poor or infrequent news from the BOD is basically a crime against investers. Very much the case here..
As I said few times, in my opinion we should hear something by 09/05 and I still think the same. It could be tomorrow or any day otherwise I don't know what the CEO going to present to the investors next Thursday. Not long to go now.
Well that depends on what the news is.....and, maybe more importantly, how the BoD word the RNS. Up until now they've been a little lacklustre in making a fuss and promoting themselves and their work. Lets just hope they can ring the bells and blow the whistles when they announce the start of phase 1!
as we all know....typically RNS day for VAL. Who knows, maybe we'll get one..... Understand what Sheephatch has been stating about drugs being pushed through quicker but, as has already been pointed out, we are some way from that. Lets get through phase 1 first.... Hopefully some excitement tomorrow..........
The medical professionals would still want to see a swathe of positive data, not going to try anything and everything, because the likelihood of a lawsuit is reduced. Val are still a way from that, but are all in at the ground floor.
Interesting to see some people are getting a little bit bored, its definitely proving to be a lengthy wait indeed, personally i am still deciding what/when i will sell, I feel like selling before phase 1 results is a bad idea but of course theres plenty to consider in between, One of my growing concerns is the "Management", They aren't that brilliant with RNS wording and clarity of info and also made a few big promises that haven't materialised as of yet which has left most of us to speculate heavily for the last few months. My final decision on selling will be on the back of how big the next rise will be and if i decided to hold then how good the data from the trials is and what kind of future information the BoD can give. Obviously there will be a dilution at some point either before or after phase 1 trial results.hmmmmm Plenty of things to consider Luckily buying more shares is not one of them for me. GLA
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.